Elizabeth Masson-Hurlburt
Corporate Officer/Principal bei CORMEDIX INC.
Vermögen: 192 483 $ am 31.03.2024
Profil
Elizabeth Masson-Hurlburt is currently the Chief Clinical Strategy & Operations Officer at CorMedix, Inc. Prior to her current position, she worked as the Vice President-Clinical Operations at Gemphire Therapeutics, Inc. from 2016 to 2018.
Ms. Masson-Hurlburt completed her undergraduate degree at Bay Path College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CORMEDIX INC.
0,08% | 12.01.2024 | 45 397 ( 0,08% ) | 192 483 $ | 31.03.2024 |
Aktive Positionen von Elizabeth Masson-Hurlburt
| Unternehmen | Position | Beginn |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Elizabeth Masson-Hurlburt
| Unternehmen | Position | Ende |
|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.03.2018 |
Ausbildung von Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
